Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,531JPY
24 Feb 2017
Change (% chg)

¥2 (+0.10%)
Prev Close
¥1,530
Open
¥1,530
Day's High
¥1,534
Day's Low
¥1,520
Volume
6,767,000
Avg. Vol
7,984,627
52-wk High
¥1,779
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,297,503.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.16

Financials

  4503.T Industry Sector
P/E (TTM): 15.63 28.84 29.63
EPS (TTM): 97.93 -- --
ROI: 14.68 13.44 12.96
ROE: 15.78 14.34 14.11

BRIEF-Astellas says to buy back up to 1.43 pct of own shares worth 50 bln yen

* to buy back up to 1.43 percent of own shares worth 50 billion yen Further company coverage:

Jan 30 2017

BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan

* Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan

Jan 29 2017

Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)

Jan 24 2017

CORRECTED-UPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19)

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 24 2017

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

Jan 10 2017

BRIEF-Astellas to acquire Ganymed Pharmaceuticals 422 mln euros

* Atellas will pay eur 422 million to acquire 100% of equity in Gnymed

Oct 28 2016

BRIEF-Astellas to buy Ganymed Pharmaceuticals for 422 mln euros

* Astellas says to buy Ganymed Pharmaceuticals for EUR 422 million ($460 million)

Oct 27 2016

BRIEF-Astellas Pharma Inc's operating profit likely rose roughly 20% on the year for April-September half - Nikkei

* Astellas Pharma Inc's operating profit likely rose roughly 20% on the year to 160 billion yen ($1.54 billion) or so for April-September half - Nikkei

Oct 21 2016

Fitch Assigns First-Time 'BBB-' Rating to Beijing Capital Development

(The following statement was released by the rating agency) HONG KONG, October 20 (Fitch) Fitch Ratings has assigned Beijing Capital Development Holding (Group) Co., Ltd. (known by its abbreviated Chinese name Shokai Group) a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'BBB-' with Stable Outlook. Fitch has also assigned the homebuilder a foreign-currency senior unsecured rating of 'BBB-'. Fitch has also assigned Bright Galaxy International Limited's (Bright Galaxy) proposed US

Oct 20 2016

BRIEF-Astellas Pharma files lawsuit against patent infringement of Myrbetriq in U.S.

* Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas' mirabegron (generic name) product sold under the trademark Myrbetriq in the U.S.

Oct 06 2016

More From Around the Web

Earnings vs. Estimates